Natural Killer (NK) Cell Therapy Pipeline

DelveInsight’s Natural Killer (NK) Cell Therapy pipeline and competitive landscape report provide an in-depth assessment of the Natural Killer (NK) Cell Therapy technologies, market dynamics, and pipeline drug profiles, including clinical and non-clinical stage products.

Key Takeaways from the Natural Killer (NK) Cell Therapy Pipeline Report 

• The major companies present in the Natural Killer Cell Therapy market are Kiadis Pharma, Nektar Therapeutics, GT Biopharma, Rubius Therapeutics, Acepodia, Fate Therapeutics, Senti Biosciences, NantKwest, Dragonfly Therapeutics, Nkarta Therapeutics, and others.

• The NK Cell Therapy pipeline technologies and drugs in the different developmental stages include haNK Platform, TriNKET Technology, Natural Killer cells Platform, K-NK002, NKTR-255, GTB 3550, RTX-240, ACE-1702, FT516, K-NK004, SENTI-202, and others. 

• The US Food and Drug Administration (FDA) granted XNK Therapeutics Orphan Drug Designation in November 2020 for its investigational drug candidate (ACP-001) for the treatment of multiple myeloma.

• Kuur Therapeutics announced the launch of its new business in March 2020 in collaboration with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Kuur Therapeutics, based in Houston, will carry on the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its novel chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.

• Acepodia’s ACC (Antibody-Cell Conjugation) technology platform attaches tumor-targeting antibodies to the surface of a unique human natural killer cell line (Natural Killer Cell Therapies). The capacity of antibody-directed Natural Killer Cell Therapies to cure human tumors provides a new and powerful therapeutic strategy to treat human cancers, particularly those with a high risk of spreading.

• Fate Therapeutics and Janssen Biotech signed a global collaboration and option agreement in April 2020. Janssen will supply unique antigen-binding domains for up to four tumor-associated antigen targets as part of the multi-year collaborative arrangement. The company plans to use its iPSC product platform to investigate and test new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates in the clinic.

Request for the sample to know which pipeline technology or drug will grab maximum attention @ Natural Killer Cell Therapy Pipeline Analysis

Natural Killer Cell Therapy: Overview

Natural Killer (NK) Cells are lymphocytes that are related to T and B cells and are derived from the same progenitor. NK cells, on the other hand, are categorized as a group I Innate Lymphocytes (ILCs) and respond promptly to a variety of pathogenic stimuli as cells of the innate immune system. NK cells are most known for their ability to eliminate virally infected cells as well as to detect and control early cancer indications. Specialized NK cells are located in the placenta and may play a crucial role in pregnancy in addition to defending against illness.

Natural Killer Cell Therapy Pipeline Analysis: Drug Profiles 

ACP-001:  XNK Therapeutics

Product Description

XNK Therapeutics is developing ACP-001, an autologous NK cell-based immunotherapy for Multiple Myeloma and other kinds of cancer. 

Phase I/II

EudraCT No: 2010-0223330-83: At the Hematology Center, Karolinska University Hospital, Stockholm, Sweden, a first-in-human phase I/II clinical trial with CellProtect was done in patients newly diagnosed with Multiple Myeloma as part of consolidation treatment after high-dose autologous stem cell transplantation. The clinical trial was an open, single-arm, triple escalating dose/patient trial with the primary goal of determining the product’s safety and tolerability. The product was found to be extremely safe, with no serious adverse events (SAE) reported.

Natural Killer Cell Therapy Pipeline Analysis: Technology Profiles

TriNKET Technology: Dragonfly Therapeutics

The patented TriNKETs provide an active link between cancer cells and immune system cells such as NK cells, T cells, B cells, and other cells that aid in the attack and killing of cancer.

Their goal is to significantly improve immunotherapy using the TriNKET platform, which is based on NK cells. Dragonfly’s technique for engaging NK cells with tumor targets can be used to treat a wide range of tumors, both directly killing cancers and improving the outcomes of other immunotherapy approaches such as T-cell therapies.

haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest

Product Description

NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio’s IL-15 superagonist for the treatment of advanced refractory metastatic Merkel cell carcinoma patients.

Phase II

NCT03853317: NantKwest launched a Phase 2 study titled “QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-Shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor” in February 2020.

Natural Killer Cell Therapy Pipeline Technologies/Therapies and Key Companies 

• K-NK002: Kiadis Pharma

• NKTR-255: Nektar Therapeutics

• GTB 3550: GT Biopharma

• RTX-240: Rubius Therapeutics

• ACE-1702: Acepodia

• FT516: Fate Therapeutics

• K-NK004: Kiadis Pharma

• SENTI-202: Senti Biosciences

• haNK Platform: NantKwest

• TriNKET Technology: Dragonfly Therapeutics

• Natural Killer cells Platform: Nkarta Therapeutics

Learn more about the emerging drugs and companies @ Natural Killer Cell Therapy Pipeline Drugs and Key Companies 

Natural Killer Cell Therapy Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Indications

• Bladder Cancers

• Solid Tumors

• By Inactive Product Analysis

• Dormant

• Discontinued

Scope of the Report

Coverage: Global

Natural Killer Cell Therapy Key Players: Kiadis Pharma, Nektar Therapeutics, GT Biopharma, Rubius Therapeutics, Acepodia, Fate Therapeutics, Senti Biosciences, NantKwest, Dragonfly Therapeutics, Nkarta Therapeutics, among others

Natural Killer Cell Therapy Pipeline Technologies/Therapies: haNK Platform, TriNKET Technology, Natural Killer cells Platform, K-NK002, NKTR-255, GTB 3550, RTX-240, ACE-1702, FT516, K-NK004, SENTI-202,  and others

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the Natural Killer Cell Therapy Pipeline Report

• What are Natural Killer Cell Therapies, and what role do they play in the treatment of disease conditions?

• How many Natural Killer Cell Therapies are developed by each company to treat disease conditions?

• What clinical trials are being conducted for Natural Killer Cell Therapies, and how far along are they?

• What are the current and upcoming Natural Killer Cell Therapies technologies?

• What are the most important collaborations (industry–industry, industry-academia), mergers and acquisitions, and licensing activities involving Natural Killer Cell Therapies therapies?

Related Reports

Natural Killer (NK)-Cell Lymphoma Pipeline Insight

“Natural Killer (NK)-Cell Lymphoma Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Natural Killer (NK)-Cell Lymphoma market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/